Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 18 min ago
Peer-reviewedCC BY 4.0Biomolecules

FABP3, a Candidate Biomarker of Muscle Strength and Myositis Disease Activity in Patients with Idiopathic Inflammatory Myopathies

  • Dorottya Szinay1,2
  • Katalin Szabó1,2
  • Tibor Béldi1,2
  • Viktor Bencs2,3
  • Sára Csiha4
  • Béla Nagy5
  • Hajnalka Lőrincz6
  • Mariann Harangi6,7
  • Zoltán Griger1,2
  • Melinda Nagy-Vincze1,2
7 affiliations
  1. 1Division of Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary
  2. 2Doctoral School of Medical Sciences, University of Debrecen, H-4032 Debrecen, Hungary
  3. 3Department of Neurology, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary
  4. 4Department of Clinical Basics, Faculty of Pharmacy, University of Debrecen, H-4032 Debrecen, Hungary
  5. 5Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary
  6. 6Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary
  7. 7Faculty of Health Sciences, Institute of Health Studies, University of Debrecen, H-4032 Debrecen, Hungary
Read full textPDFDOICite

Abstract

Background: Identifying novel, reliable blood-based biomarkers is essential to better assess disease activity in idiopathic inflammatory myopathies (IIMs). We aimed to determine serum fatty acid binding protein 3 (FABP3) levels in IIM patients and evaluated their correlations with disease activity, muscle strength, and conventional biomarkers. Methods: This cross-sectional study enrolled 80 patients with IIM (49% polymyositis, 51% dermatomyositis) and 47 gender-matched healthy controls. Disease activity was evaluated using the IMACS core set measures, and serum FABP3 levels were determined via ELISA. Results: FABP3 levels significantly correlated with creatine kinase (CK; r = 0.42, p < 0.001), high-sensitive C-reactive protein (hsCRP; r = 0.35, p = 0.002), and physician global disease activity (PhG; r = 0.28, p = 0.013), while showing a strong negative correlation with manual muscle testing (MMT; r = −0.39, p = 0.0005). Conversely, CK and hsCRP failed to correlate with disease activity or muscle strength. Statistical analysis confirmed that FABP3 is an independent predictor of muscle strength, and correlates with PhG better than CK in patients with chronic myositis. Conclusions: FABP3 is a promising biomarker for IIM disease activity, which may enable more effective therapeutic decision-making in clinical practice.

Related

  1. Trends in Hospitalizations of Patients with Idiopathic Inflammatory Myopathies: Long-Term Observational Study, 2010–2024
    Maria Dutsch-Wicherek, Bartłomiej Wieleba, Katarzyna Lewtak +3
    Journal of clinical medicinePeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCCrossref
  2. Increased IL-23 is Associated to Heliotrope Sign in Multivariate Model on Idiopathic Inflammatory Myopathies.
    Christian Juarez-Gomez, Oscar Pizano-Martinez, María Guadalupe Ramírez-Dueñas +5
    Dermatology research and practicePeer-reviewedCC BYFull textEpidemiology & public healthEurope PMC
  3. A comparative analysis of semiannual versus annual rituximab maintenance in patients with refractory idiopathic inflammatory myopathies: a retrospective longitudinal real-world study.
    Rodrigo Lorenzetti Serrano, Fernando Henrique Carlos de Souza, Renata Miossi +2
    Revista da Associacao Medica Brasileira (1992)Peer-reviewedCC BYFull textEpidemiology & public healthEurope PMC
  4. Cardiovascular risk stratification using chest CT in idiopathic inflammatory myopathies.
    Kastriot Kastrati, Svitlana Pochepnia, Rade Drača +9
    Rheumatology (Oxford, England)Peer-reviewedCC BYFull textMedical imaging & radiologyEurope PMC
  5. Organ-specific digestive system cancer risks in idiopathic inflammatory myopathies: a systematic review and meta-analysis
    YaWen Zhu, Ai Qian, YuanYuan Cheng +2
    Scientific ReportsPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossref

Cite

BibTeXRIS
BibTeX
@article{szinay2026fabp3,
  title = {{FABP3, a Candidate Biomarker of Muscle Strength and Myositis Disease Activity in Patients with Idiopathic Inflammatory Myopathies}},
  author = {Dorottya Szinay and Katalin Szabó and Tibor Béldi and Viktor Bencs and Sára Csiha and Béla Nagy and Hajnalka Lőrincz and Mariann Harangi and Zoltán Griger and Melinda Nagy-Vincze},
  journal = {Biomolecules},
  year = {2026},
  month = oct,
  doi = {10.3390/biom16101518},
  url = {https://www.mdpi.com/2218-273X/16/10/1518},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - FABP3, a Candidate Biomarker of Muscle Strength and Myositis Disease Activity in Patients with Idiopathic Inflammatory Myopathies
AU  - Dorottya Szinay
AU  - Katalin Szabó
AU  - Tibor Béldi
AU  - Viktor Bencs
AU  - Sára Csiha
AU  - Béla Nagy
AU  - Hajnalka Lőrincz
AU  - Mariann Harangi
AU  - Zoltán Griger
AU  - Melinda Nagy-Vincze
PY  - 2026
DA  - 2026/10/01
JO  - Biomolecules
DO  - 10.3390/biom16101518
UR  - https://www.mdpi.com/2218-273X/16/10/1518
AB  - Background: Identifying novel, reliable blood-based biomarkers is essential to better assess disease activity in idiopathic inflammatory myopathies (IIMs). We aimed to determine serum fatty acid binding protein 3 (FABP3) levels in IIM patients and evaluated their correlations with disease activity, muscle strength, and conventional biomarkers. Methods: This cross-sectional study enrolled 80 patients with IIM (49% polymyositis, 51% dermatomyositis) and 47 gender-matched healthy controls. Disease activity was evaluated using the IMACS core set measures, and serum FABP3 levels were determined via ELISA. Results: FABP3 levels significantly correlated with creatine kinase (CK; r = 0.42, p < 0.001), high-sensitive C-reactive protein (hsCRP; r = 0.35, p = 0.002), and physician global disease activity (PhG; r = 0.28, p = 0.013), while showing a strong negative correlation with manual muscle testing (MMT; r = −0.39, p = 0.0005). Conversely, CK and hsCRP failed to correlate with disease activity or muscle strength. Statistical analysis confirmed that FABP3 is an independent predictor of muscle strength, and correlates with PhG better than CK in patients with chronic myositis. Conclusions: FABP3 is a promising biomarker for IIM disease activity, which may enable more effective therapeutic decision-making in clinical practice.
SN  - 2218-273X
ER  -